Daniela Massi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5118830/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Disseminated Talaromyces infection in an AIDS patient. Clinical Microbiology and Infection, 2022, 28, 64-65.	2.8	2
2	Overexpression of helper T cell type 2-related molecules in the skin of patients with eosinophilic dermatosis of hematologic malignancy. Journal of the American Academy of Dermatology, 2022, 87, 761-770.	0.6	9
3	The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts. Cancers, 2022, 14, 377.	1.7	17
4	Atypical Spitz Tumors: An epidemiological, clinical and dermoscopic multicenter study with 16â€year followâ€up. Clinical and Experimental Dermatology, 2022, , .	0.6	4
5	Porocarcinoma: an epidemiological, clinical, and dermoscopic 20â€year study. International Journal of Dermatology, 2022, 61, 1098-1105.	0.5	4
6	NTRK Fusions Detection in Paediatric Sarcomas to Expand the Morphological Spectrum and Clinical Relevance of Selected Entities. Pathology and Oncology Research, 2022, 28, 1610237.	0.9	2
7	Tumors carrying BRAF-mutations over-express NAMPT that is genetically amplified and possesses oncogenic properties. Journal of Translational Medicine, 2022, 20, 118.	1.8	3
8	Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review. International Journal of Molecular Sciences, 2022, 23, 147.	1.8	8
9	Conceptual Evolution and Current Approach to Spitz Tumors. Dermatopathology (Basel, Switzerland), 2022, 9, 136-142.	0.7	2
10	Folliculotropism in head and neck lentigo maligna and lentigo maligna melanoma. JDDG - Journal of the German Society of Dermatology, 2021, 19, 223-229.	0.4	5
11	Germline <i>MC1R</i> variants and frequency of somatic <i>BRAF, NRAS</i> , and <i>TERT</i> mutations in melanoma: Literature review and metaâ€analysis. Molecular Carcinogenesis, 2021, 60, 167-171.	1.3	5
12	ESP, EORTC, and EURACAN Expert Opinion: practical recommendations for the pathological diagnosis and clinical management of intermediate melanocytic tumors and rare related melanoma variants. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 3-11.	1.4	26
13	Multitarget fluorescence in situ hybridization diagnostic applications in solid and hematological tumors. Expert Review of Molecular Diagnostics, 2021, 21, 161-173.	1.5	2
14	Clinical and dermoscopic polymorphisms in agminated Spitz nevi: Ugly presentation but benign behavior. Pediatric Dermatology, 2021, 38, 461-463.	0.5	1
15	Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients. Cells, 2021, 10, 422.	1.8	6
16	Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?. American Journal of Clinical Dermatology, 2021, 22, 511-522.	3.3	6
17	NCS-Based Analysis of Atypical Deep Penetrating Nevi. Cancers, 2021, 13, 3066.	1.7	10
18	An Upgrade of Apparatus and Measurement Systems for Generation of Gaseous Formaldehyde: A Review. Critical Reviews in Analytical Chemistry, 2021, , 1-15.	1.8	0

#	Article	IF	CITATIONS
19	Formalin safety in anatomic pathology workflow and integrated air monitoring systems for the formaldehyde occupational exposure assessment. International Journal of Occupational Medicine and Environmental Health, 2021, 34, 319-338.	0.6	6
20	Videodermoscopic folliculotropism as a sign of lentigo maligna in the fluorescenceâ€advanced videodermatoscopy (FAV). Skin Research and Technology, 2021, 27, 1172-1173.	0.8	0
21	Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms. American Journal of Surgical Pathology, 2021, 45, 1597-1605.	2.1	16
22	Sigurnost rada u anatomskom laboratoriju s formalinom i inovativno praćenje procjene profesionalne izloženosti formaldehidu. Sigurnost, 2021, 63, 165-180.	0.0	0
23	Editorial: Advancements in Molecular Diagnosis and Treatment of Melanoma. Frontiers in Oncology, 2021, 11, 728113.	1.3	1
24	Treatment of periocular advanced basal cell carcinoma with Hedgehog pathway inhibitors: a single-center study and a new dedicated therapeutic protocol. Dermatology Reports, 2021, 13, 9240.	0.4	3
25	Sweet Syndrome Following SARS-CoV2 Vaccination. Vaccines, 2021, 9, 1212.	2.1	16
26	Fluorescenceâ€advanced videodermatoscopy (FAV) for the differential diagnosis of suspicious facial lesions: a singleâ€centre experience with pattern analysis and histopathological correlation. Photodermatology Photoimmunology and Photomedicine, 2021, , .	0.7	0
27	NTRK Gene Fusion Detection in Atypical Spitz Tumors. International Journal of Molecular Sciences, 2021, 22, 12332.	1.8	12
28	Nevi and Breslow thickness in melanoma: sex differences?. Melanoma Research, 2020, 30, 179-184.	0.6	2
29	Eyelid skin metastasis as first sign of breast cancer recurrence. Breast Journal, 2020, 26, 2416-2417.	0.4	1
30	BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients. Critical Reviews in Oncology/Hematology, 2020, 156, 103118.	2.0	17
31	SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessment. European Journal of Cancer, 2020, 137, 175-182.	1.3	27
32	Clinical and Dermoscopic Features of Vulvar Melanosis Over the Last 20 Years. JAMA Dermatology, 2020, 156, 1185.	2.0	15
33	TRPA1 Expression in Synovial Sarcoma May Support Neural Origin. Biomolecules, 2020, 10, 1446.	1.8	6
34	Granulomatous Dermatitis and Systemic Disease: An Association to Consider. BioMed Research International, 2020, 2020, 1-6.	0.9	3
35	Scalp spiradenocylindroma: A challenging dermoscopic diagnosis. Dermatologic Therapy, 2020, 33, e14307.	0.8	0
36	Recognition of Cutaneous Melanoma on Digitized Histopathological Slides via Artificial Intelligence Algorithm. Frontiers in Oncology, 2020, 10, 1559.	1.3	38

#	Article	lF	CITATIONS
37	Re-irradiation for oligoprogression under Nivolumab in recurrent head and neck squamous cell carcinoma: A case report. Clinical and Translational Radiation Oncology, 2020, 23, 16-19.	0.9	6
38	TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions. Critical Reviews in Oncology/Hematology, 2020, 152, 103011.	2.0	12
39	Melanoma brain metastases: review of histopathological features and immune-molecular aspects. Melanoma Management, 2020, 7, MMT44.	0.1	8
40	Congenital circumscribed plantar hypokeratosis. International Journal of Dermatology, 2020, 59, e367-e369.	0.5	7
41	Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications. Cancer Treatment Reviews, 2020, 88, 102060.	3.4	27
42	The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway. Archives of Pathology and Laboratory Medicine, 2020, 144, 500-522.	1.2	239
43	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. Clinical Cancer Research, 2020, 26, 3671-3681.	3.2	53
44	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nature Genetics, 2020, 52, 494-504.	9.4	138
45	Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain. Journal of the American Academy of Dermatology, 2020, 83, 860-869.	0.6	5
46	How improvements in monitoring and safety practices lowered airborne formaldehyde concentrations at an Italian university hospital: a summary of 20 years of experience. Arhiv Za Higijenu Rada I Toksikologiju, 2020, 71, 178-189.	0.4	2
47	The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. , 2019, 7, 308.		51
48	Evaluation of the liquid biopsy for the detection of BRAFV600E mutation in metastatic melanoma patients. Cancer Biomarkers, 2019, 26, 271-279.	0.8	7
49	Machine versus man in skin cancer diagnosis. Lancet Oncology, The, 2019, 20, 891-892.	5.1	3
50	An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanoma. European Journal of Cancer, 2019, 114, 1-7.	1.3	38
51	MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. The Lancet Child and Adolescent Health, 2019, 3, 332-342.	2.7	16
52	Fluorescenceâ€advanced videodermatoscopy: A promising and potential technique for the in vivo evaluation of vitiligo. Dermatologic Therapy, 2019, 32, e12863.	0.8	4
53	Prognostic impact of regression in patients with primary cutaneous melanoma >1Âmm in thickness. Journal of the American Academy of Dermatology, 2019, 80, 99-105.e5.	0.6	19
54	Melanoma types by in vivo reflectance confocal microscopy correlated with protein and molecular genetic alterations: AÂpilot study. Experimental Dermatology, 2019, 28, 254-260.	1.4	6

#	Article	IF	CITATIONS
55	A Critical Reappraisal of Primary and Recurrent Advanced Laryngeal Cancer Staging. Annals of Otology, Rhinology and Laryngology, 2019, 128, 36-43.	0.6	12
56	Eosinophilic dermatosis of hematologic malignancy: A retrospective cohort of 37 patients from an Italian center. Journal of the American Academy of Dermatology, 2019, 81, 246-249.	0.6	28
57	ECCO essential requirements for quality cancer care: Melanoma. Critical Reviews in Oncology/Hematology, 2018, 122, 164-178.	2.0	41
58	Venous outlet syndrome caused by capillary hemangioma of the subclavian vein. Asian Cardiovascular and Thoracic Annals, 2018, 26, 224-226.	0.2	0
59	Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma. Journal of the National Cancer Institute, 2018, 110, 290-303.	3.0	32
60	Multimodal image analysis in tissue diagnostics for skin melanoma. Journal of Chemometrics, 2018, 32, e2963.	0.7	14
61	Improved labelâ€free diagnostics and pathological assessment of atherosclerotic plaques through nonlinear microscopy. Journal of Biophotonics, 2018, 11, e201800106.	1.1	6
62	Clinical and Dermoscopic Features of Lichenoid Keratosis: A Retrospective Case Study. Journal of Cutaneous Medicine and Surgery, 2018, 22, 561-566.	0.6	9
63	At the Root: Cutaneous Langerhans Cell Histiocytosis. American Journal of Medicine, 2018, 131, 922-926.	0.6	3
64	MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the melanostrum consortium. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2134-2141.	1.3	9
65	Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma. Oncotarget, 2018, 9, 18997-19005.	0.8	25
66	Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma. Handbook of Experimental Pharmacology, 2017, 249, 129-143.	0.9	3
67	Droplet digital PCR (ddPCR) vs quantitative real-time PCR (qPCR) approach for detection and quantification of Merkel cell polyomavirus (MCPyV) DNA in formalin fixed paraffin embedded (FFPE) cutaneous biopsies. Journal of Virological Methods, 2017, 246, 15-20.	1.0	41
68	Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy. American Journal of Clinical Dermatology, 2017, 18, 597-611.	3.3	11
69	Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients. European Journal of Cancer, 2017, 78, 70-81.	1.3	42
70	Virchows Archiv—an update, and plans for the future. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 3-4.	1.4	2
71	Role of BMI and hormone therapy in melanoma risk: a case–control study. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1191-1197.	1.2	18
72	Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation. Laboratory Investigation, 2017, 97, 166-175.	1.7	37

#	Article	IF	CITATIONS
73	Bullous eruption in a patient with Bâ€cell chronic lymphocytic leukemia: a diagnostic challenge. International Journal of Dermatology, 2017, 56, 1445-1447.	0.5	11
74	Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1Âmillimeter in thickness: A multi-institutional study of 1524 cases. Journal of the American Academy of Dermatology, 2017, 76, 264-273.e2.	0.6	41
75	PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p. Oncotarget, 2017, 8, 15894-15911.	0.8	84
76	Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases. Journal of Translational Medicine, 2017, 15, 227.	1.8	10
77	mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. Oncotarget, 2017, 8, 69204-69218.	0.8	21
78	Teledermoscopy in doubtful melanocytic lesions: is it really useful?. International Journal of Dermatology, 2016, 55, 1119-1123.	0.5	12
79	Wnt/β-catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights. Cancer Treatment Reviews, 2016, 49, 1-12.	3.4	85
80	Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling. Physiological Reviews, 2016, 96, 805-829.	13.1	49
81	Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors. Journal of the American Academy of Dermatology, 2016, 74, 1254-1256.e4.	0.6	9
82	Estrogen receptor (ER) \hat{I}^2 expression and worse outcome from melanoma in pregnant and perimenopausal women. Journal of the American Academy of Dermatology, 2016, 75, e117.	0.6	6
83	PD-L1 in melanoma: facts and myths. Melanoma Management, 2016, 3, 187-194.	0.1	11
84	The complex management of atypical Spitz tumours. Pathology, 2016, 48, 132-141.	0.3	15
85	Detection of Merkel cell polyomavirus and human papillomavirus DNA in porocarcinoma. Journal of Clinical Virology, 2016, 78, 71-73.	1.6	14
86	PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2016, 100, 88-98.	2.0	316
87	Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Modern Pathology, 2016, 29, 347-358.	2.9	43
88	AKT-ions with a TWIST between EMT and MET. Oncotarget, 2016, 7, 62767-62777.	0.8	71
89	Epidemiological features and prognostic parameters of multiple primary melanomas inCDKN2A-mutations patients. Pigment Cell and Melanoma Research, 2015, 28, 747-751.	1.5	2
90	Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma. Modern Pathology, 2015, 28, 487-497.	2.9	59

#	Article	IF	CITATIONS
91	Integrated Akt/PKB Signaling in Immunomodulation and Its Potential Role in Cancer Immunotherapy. Journal of the National Cancer Institute, 2015, 107, djv171-djv171.	3.0	78
92	KIT genetic alterations in anorectal melanomas. Journal of Clinical Pathology, 2015, 68, 130-134.	1.0	27
93	Atypical Spitz tumors in patients younger than 18 years. Journal of the American Academy of Dermatology, 2015, 72, 37-46.	0.6	77
94	Tumor-Related Methylated Cell-Free DNA and Circulating Tumor Cells in Melanoma. Frontiers in Molecular Biosciences, 2015, 2, 76.	1.6	28
95	Circulating Tumor Cells Detection and Counting in Uveal Melanomas by a Filtration-Based Method. Cancers, 2014, 6, 323-332.	1.7	54
96	In-vivo imaging of psoriatic lesions with polarization multispectral dermoscopy and multiphoton microscopy. Biomedical Optics Express, 2014, 5, 2405.	1.5	31
97	Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities. Critical Reviews in Oncology/Hematology, 2014, 89, 140-165.	2.0	148
98	Nras in melanoma: Targeting the undruggable target. Critical Reviews in Oncology/Hematology, 2014, 92, 107-122.	2.0	67
99	Transient Receptor Potential Vanilloid 4 (TRPV4) Is Downregulated in Keratinocytes in Human Non-Melanoma Skin Cancer. Journal of Investigative Dermatology, 2014, 134, 2408-2417.	0.3	63
100	Impact of low-thermal-injury devices on margin status in laryngeal cancer. An experimental ex vivo study. Oral Oncology, 2014, 50, 32-39.	0.8	21
101	Hapten-Specific Th17 Cells in the Peripheral Blood of β-Lactam-Induced AGEP. Allergology International, 2014, 63, 129-131.	1.4	7
102	BRAF and KIT somatic mutations are present in amelanotic melanoma. Melanoma Research, 2013, 23, 414-419.	0.6	20
103	Different prevalence of <i>BRAF</i> and <i>NRAS</i> somatic mutations in melanomas according to the patients' origin Journal of Clinical Oncology, 2013, 31, e20013-e20013.	0.8	0
104	Atypical Spitzoid melanocytic tumors: AÂmorphological, mutational, and FISH analysis. Journal of the American Academy of Dermatology, 2011, 64, 919-935.	0.6	66
105	The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo. Human Pathology, 2011, 42, 254-268.	1.1	17
106	Primary cutaneous leiomyosarcoma: clinicopathological analysis of 36 cases. Histopathology, 2010, 56, 251-262.	1.6	106
107	S100A13 is a new angiogenic marker in human melanoma. Modern Pathology, 2010, 23, 804-813.	2.9	61
108	Acetaminophen,viaits reactive metabolite Nâ€acetylâ€pâ€benzoâ€quinoneimine and transient receptor potential ankyrinâ€1 stimulation, causes neurogenic inflammation in the airways and other tissues in rodents. FASEB Journal, 2010, 24, 4904-4916.	0.2	19

#	Article	IF	CITATIONS
109	Inducible nitric oxide synthase expression in melanoma: implications in lymphangiogenesis. Modern Pathology, 2009, 22, 21-30.	2.9	38
110	Primary cutaneous osteosarcoma of the scalp: a case report and review of the literature. Journal of Cutaneous Pathology, 2007, 34, 61-64.	0.7	33
111	Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma. Modern Pathology, 2006, 19, 246-254.	2.9	97
112	Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Human Pathology, 2005, 36, 676-685.	1.1	67
113	Vasculogenic mimicry has no prognostic significance in pT3 and pT4 cutaneous melanoma. Human Pathology, 2004, 35, 496-502.	1.1	31
114	Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin. Human Pathology, 2003, 34, 80-88.	1.1	39
115	Simultaneous occurrence of multiple melanoma in situ on sundamaged skin (lentigo maligna), solar lentigo and labial melanosis: the value of dermoscopy in diagnosis. Journal of the European Academy of Dermatology and Venereology, 1999, 13, 193-197.	1.3	12
116	Clinical diagnosis and therapy of cutaneous melanoma in situ. , 1996, 78, 1140-1141.		0